High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases
Authors:
- Domenico CianfloneDCDomenico Cianflone
- Alessandro DuranteAlessandro Durante
- Enrico AmmiratiEAEnrico Ammirati
- Diego VanuzzoDVDiego Vanuzzo
- Michela BanfiMBMichela Banfi
- Giliola CaloriGCGiliola Calori
- Azeem LatibAzeem Latib
- Filippo CreaFCFilippo Crea
- Giancarlo MarenziGiancarlo Marenzi
- Monica De MetrioMMMonica De Metrio
- Luciano MorettiLMLuciano Moretti
Abstract
No abstract availableKeywords
Funding Information
- Fondazione per il Cuore ONLUS Roma
- nonprofit organization
- Ministero dell'istruzione dell'università e della ricerca (FIRB RBAU01FSA4)
- Regione Friuli
This publication has 17 references indexed in Scilit:
- Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)Journal of Thrombosis and Haemostasis, 2009
- Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary SyndromesArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- States, rates and traits: prognosis research and chronic stable anginaHeart, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- C‐reactive protein and coronary heart disease: a critical reviewJournal of Internal Medicine, 2008
- Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic ReviewPLOS Medicine, 2008
- Use and Misuse of the Receiver Operating Characteristic Curve in Risk PredictionCirculation, 2007
- Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialEuropean Heart Journal, 2005
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populationsThe Lancet, 1999